The serrated pathway to colorectal carcinoma: Current concepts and challenges

Histopathology

Volumn 62, Issue 3, 2013, Pages 367-386

  Bettington, Mark ^a,b,c   Walker, Neal ^a,c   Clouston, Andrew ^a,c,d   Brown, Ian ^c,d   Leggett, Barbara ^a,b,e   Whitehall, Vicki ^b,d  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^c Envoi Specialist Pathologists   (Australia)

^d Pathology Queensland   (Australia)

^e ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Colonic polyps; Colorectal neoplasms; Histopathology; Large intestine; Serrated neoplasia pathway

Indexed keywords

B RAF KINASE; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE;

CANCER GROWTH; COLORECTAL CARCINOMA; CPG ISLAND; CYTOLOGY; DNA METHYLATION; DYSPLASIA; FIBROBLASTIC POLYP; GENE MUTATION; GOBLET CELL HYPERPLASTIC POLYP; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; HYPERPLASTIC POLYP; METHYLATION; MICROSATELLITE INSTABILITY; MICROVESICULAR HYPERPLASIC POLYP; MUCIN POOR HYPERPLASTIC POLYP; MUTANT; POLYP; PRIORITY JOURNAL; RECTUM ADENOMA; REVIEW; SESSILE SERRATED ADENOMA WITH DYSPLASIA;

COLONIC POLYPS; COLORECTAL NEOPLASMS; HUMANS; PRECANCEROUS CONDITIONS;

EID: 84872670401     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12055     Document Type: Review

References (116)

1. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007; 50; 113-130.
2. Snover DC. Update on the serrated pathway to colorectal carcinoma. Hum. Pathol. 2011; 42; 1-10.
3. Vogelstein B, Fearon ER, Hamilton SR et al. Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 1988; 319; 525-532.
4. Williams GT, Arthur JF, Bussey HJ, Morson BC. Metaplastic polyps and polyposis of the colorectum. Histopathology 1980; 4; 155-170.
5. Bengoechea O, Martinez-Penuela JM, Larrinaga B, Valerdi J, Borda F. Hyperplastic polyposis of the colorectum and adenocarcinoma in a 24-year-old man. Am. J. Surg. Pathol. 1987; 11; 323-327.
6. Jeevaratnam P, Cottier DS, Browett PJ, Van De Water NS, Pokos V, Jass JR. Familial giant hyperplastic polyposis predisposing to colorectal cancer: a new hereditary bowel cancer syndrome. J. Pathol. 1996; 179; 20-25.
7. Leggett BA, Devereaux B, Biden K, Searle J, Young J, Jass J. Hyperplastic polyposis: association with colorectal cancer. Am. J. Surg. Pathol. 2001; 25; 177-184.
8. Orii S, Nakamura S, Sugai T et al. Hyperplastic (metaplastic) polyposis of the colorectum associated with adenomas and an adenocarcinoma. J. Clin. Gastroenterol. 1997; 25; 369-372.
9. Franzin G, Novelli P. Adenocarcinoma occurring in a hyperplastic (metaplastic) polyp of the colon. Endoscopy 1982; 14; 28-30.
10. Torlakovic E, Snover DC. Serrated adenomatous polyposis in humans. Gastroenterology 1996; 110; 748-755.
11. Marra G, Boland CR. Hereditary nonpolyposis colorectal cancer: the syndrome, the genes, and historical perspectives. J. Natl Cancer Inst. 1995; 87; 1114-1125.
12. Markowitz S, Wang J, Myeroff L et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 1995; 268; 1336-1338.
13. Souza RF, Appel R, Yin J et al. Microsatellite instability in the insulin-like growth factor II receptor gene in gastrointestinal tumours. Nat. Genet. 1996; 14; 255-257.
14. Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 1993; 363; 558-561.
15. Aaltonen LA, Peltomaki P, Leach FS et al. Clues to the pathogenesis of familial colorectal cancer. Science 1993; 260; 812-816.
16. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993; 260; 816-819.
17. Fishel R, Lescoe MK, Rao MR et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1993; 75; 1027-1038.
18. Leach FS, Nicolaides NC, Papadopoulos N et al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 1993; 75; 1215-1225.
19. Bronner CE, Baker SM, Morrison PT et al. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature 1994; 368; 258-261.
20. Nicolaides NC, Papadopoulos N, Liu B et al. Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature 1994; 371; 75-80.
21. Papadopoulos N, Nicolaides NC, Wei YF et al. Mutation of a mutL homolog in hereditary colon cancer. Science 1994; 263; 1625-1629.
22. Rodriguez-Bigas MA, Boland CR, Hamilton SR et al. A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J. Natl Cancer Inst. 1997; 89; 1758-1762.
23. Liu B, Nicolaides NC, Markowitz S et al. Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability. Nat. Genet. 1995; 9; 48-55.
24. Gardiner-Garden M, Frommer M. CpG islands in vertebrate genomes. J. Mol. Biol. 1987; 196; 261-282.
25. Bird AP. CpG-rich islands and the function of DNA methylation. Nature 1986; 321; 209-213.
26. Issa JP. CpG island methylator phenotype in cancer. Nat. Rev. Cancer 2004; 4; 988-993.
27. Toyota M, Ho C, Ahuja N et al. Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. Cancer Res. 1999; 59; 2307-2312.
28. Kane MF, Loda M, Gaida GM et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res. 1997; 57; 808-811.
29. Cunningham JM, Christensen ER, Tester DJ et al. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res. 1998; 58; 3455-3460.
30. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc. Natl Acad. Sci. USA 1999; 96; 8681-8686.
31. Weisenberger DJ, Siegmund KD, Campan M et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat. Genet. 2006; 38; 787-793.
32. Jass JR, Young J, Leggett BA. Hyperplastic polyps and DNA microsatellite unstable cancers of the colorectum. Histopathology 2000; 37; 295-301.
33. Iino H, Jass JR, Simms LA et al. DNA microsatellite instability in hyperplastic polyps, serrated adenomas, and mixed polyps: a mild mutator pathway for colorectal cancer? J. Clin. Pathol. 1999; 52; 5-9.
34. Makinen MJ, George SM, Jernvall P, Makela J, Vihko P, Karttunen TJ. Colorectal carcinoma associated with serrated adenoma-prevalence, histological features, and prognosis. J. Pathol. 2001; 193; 286-294.
35. Makinen MJ. Colorectal serrated adenocarcinoma. Histopathology 2007; 50; 131-150.
36. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002; 418; 934.
37. Bosman FT, World Health Organization, International Agency for Research on Cancer. World Health Organization classification of tumours of the digestive system, 4th edn. Lyon: IARC, 2010.
38. Torlakovic E, Skovlund E, Snover DC, Torlakovic G, Nesland JM. Morphologic reappraisal of serrated colorectal polyps. Am. J. Surg. Pathol. 2003; 27; 65-81.
39. Estrada RG, Spjut HJ. Hyperplastic polyps of the large bowel. Am. J. Surg. Pathol. 1980; 4; 127-133.
40. Yang S, Farraye FA, Mack C, Posnik O, O'Brien MJ. BRAF and KRAS mutations in hyperplastic polyps and serrated adenomas of the colorectum: relationship to histology and CpG island methylation status. Am. J. Surg. Pathol. 2004; 28; 1452-1459.
41. Spring KJ, Zhao ZZ, Karamatic R et al. High prevalence of sessile serrated adenomas with BRAF mutations: a prospective study of patients undergoing colonoscopy. Gastroenterology 2006; 131; 1400-1407.
42. Carr NJ, Mahajan H, Tan KL, Hawkins NJ, Ward RL. Serrated and non-serrated polyps of the colorectum: their prevalence in an unselected case series and correlation of BRAF mutation analysis with the diagnosis of sessile serrated adenoma. J. Clin. Pathol. 2009; 62; 516-518.
43. Higuchi T, Sugihara K, Jass JR. Demographic and pathological characteristics of serrated polyps of colorectum. Histopathology 2005; 47; 32-40.
44. Vakiani E, Yantiss RK. Pathologic features and biologic importance of colorectal serrated polyps. Adv. Anat. Pathol. 2009; 16; 79-91.
45. Winawer SJ, Zauber AG, Fletcher RH et al. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. Gastroenterology 2006; 130; 1872-1885.
46. O'Brien MJ. Hyperplastic and serrated polyps of the colorectum. Gastroenterol. Clin. North Am. 2007; 36; 947-968, viii.
47. Goldstein NS, Bhanot P, Odish E, Hunter S. Hyperplastic-like colon polyps that preceded microsatellite-unstable adenocarcinomas. Am. J. Clin. Pathol. 2003; 119; 778-796.
48. Torlakovic EE, Gomez JD, Driman DK et al. Sessile serrated adenoma (SSA) vs. traditional serrated adenoma (TSA). Am. J. Surg. Pathol. 2008; 32; 21-29.
49. Kriegl L, Neumann J, Vieth M et al. Up and downregulation of p16(Ink4a) expression in BRAF-mutated polyps/adenomas indicates a senescence barrier in the serrated route to colon cancer. Mod. Pathol. 2011; 24; 1015-1022.
50. Bennecke M, Kriegl L, Bajbouj M et al. Ink4a/Arf and oncogene-induced senescence prevent tumor progression during alternative colorectal tumorigenesis. Cancer Cell 2010; 18; 135-146.
51. Chung SM, Chen YT, Panczykowski A, Schamberg N, Klimstra DS, Yantiss RK. Serrated polyps with 'intermediate features' of sessile serrated polyp and microvesicular hyperplastic polyp: a practical approach to the classification of nondysplastic serrated polyps. Am. J. Surg. Pathol. 2008; 32; 407-412.
52. Gibson JA, Hahn HP, Shahsafaei A, Odze RD. MUC expression in hyperplastic and serrated colonic polyps: lack of specificity of MUC6. Am. J. Surg. Pathol. 2011; 35; 742-749.
53. Mochizuka A, Uehara T, Nakamura T, Kobayashi Y, Ota H. Hyperplastic polyps and sessile serrated 'adenomas' of the colon and rectum display gastric pyloric differentiation. Histochem. Cell Biol. 2007; 128; 445-455.
54. Kambara T, Simms LA, Whitehall VL et al. BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut 2004; 53; 1137-1144.
55. Collado M, Gil J, Efeyan A et al. Tumour biology: senescence in premalignant tumours. Nature 2005; 436; 642.
56. Collado M, Blasco MA, Serrano M. Cellular senescence in cancer and aging. Cell 2007; 130; 223-233.
57. Campisi J, d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat. Rev. Mol. Cell Biol. 2007; 8; 729-740.
58. Michaloglou C, Vredeveld LC, Soengas MS et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005; 436; 720-724.
59. Tateyama H, Li W, Takahashi E, Miura Y, Sugiura H, Eimoto T. Apoptosis index and apoptosis-related antigen expression in serrated adenoma of the colorectum: the saw-toothed structure may be related to inhibition of apoptosis. Am. J. Surg. Pathol. 2002; 26; 249-256.
60. Lash RH, Genta RM, Schuler CM. Sessile serrated adenomas: prevalence of dysplasia and carcinoma in 2139 patients. J. Clin. Pathol. 2010; 63; 681-686.
61. Ensari A, Bosman FT, Offerhaus GJ. The serrated polyp: getting it right! J. Clin. Pathol. 2010; 63; 665-668.
62. Goldstein NS. Small colonic microsatellite unstable adenocarcinomas and high-grade epithelial dysplasias in sessile serrated adenoma polypectomy specimens: a study of eight cases. Am. J. Clin. Pathol. 2006; 125; 132-145.
63. Tadepalli US, Feihel D, Miller KM et al. A morphologic analysis of sessile serrated polyps observed during routine colonoscopy (with video). Gastrointest. Endosc. 2011; 74; 1360-1368.
64. Kimura T, Yamamoto E, Yamano HO et al. A novel pit pattern identifies the precursor of colorectal cancer derived from sessile serrated adenoma. Am. J. Gastroenterol. 2012; 107; 460-469.
65. Aust DE, Baretton GB. Serrated polyps of the colon and rectum (hyperplastic polyps, sessile serrated adenomas, traditional serrated adenomas, and mixed polyps)-proposal for diagnostic criteria. Virchows Arch. 2010; 457; 291-297.
66. Snover DC, Jass JR, Fenoglio-Preiser C, Batts KP. Serrated polyps of the large intestine: a morphologic and molecular review of an evolving concept. Am. J. Clin. Pathol. 2005; 124; 380-391.
67. Sheridan TB, Fenton H, Lewin MR et al. Sessile serrated adenomas with low- and high-grade dysplasia and early carcinomas: an immunohistochemical study of serrated lesions 'caught in the act'. Am. J. Clin. Pathol. 2006; 126; 564-571.
68. East JE, Saunders BP, Jass JR. Sporadic and syndromic hyperplastic polyps and serrated adenomas of the colon: classification, molecular genetics, natural history, and clinical management. Gastroenterol. Clin. North Am. 2008; 37; 25-46, v.
69. Salaria SN, Streppel MM, Lee LA, Iacobuzio-Donahue CA, Montgomery EA. Sessile serrated adenomas: high-risk lesions? Hum. Pathol. 2012; 43; 1808-1814.
70. Mohammadi M, Garbyal RS, Kristensen MH, Madsen PM, Nielsen HJ, Holck S. Sessile serrated lesion and its borderline variant-variables with impact on recorded data. Pathol. Res. Pract. 2011; 207; 410-416.
71. Fujita K, Yamamoto H, Matsumoto T et al. Sessile serrated adenoma with early neoplastic progression: a clinicopathologic and molecular study. Am. J. Surg. Pathol. 2011; 35; 295-304.
72. Jass JR, Baker K, Zlobec I et al. Advanced colorectal polyps with the molecular and morphological features of serrated polyps and adenomas: concept of a 'fusion' pathway to colorectal cancer. Histopathology 2006; 49; 121-131.
73. Leggett B, Whitehall V. Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology 2010; 138; 2088-2100.
74. Suzuki H, Watkins DN, Jair KW et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat. Genet. 2004; 36; 417-422.
75. Yachida S, Mudali S, Martin SA, Montgomery EA, Iacobuzio-Donahue CA. Beta-catenin nuclear labeling is a common feature of sessile serrated adenomas and correlates with early neoplastic progression after BRAF activation. Am. J. Surg. Pathol. 2009; 33; 1823-1832.
76. Dhir M, Yachida S, Van Neste L et al. Sessile serrated adenomas and classical adenomas: an epigenetic perspective on premalignant neoplastic lesions of the gastrointestinal tract. Int. J. Cancer 2011; 129; 1889-1898.
77. Longacre TA, Fenoglio-Preiser CM. Mixed hyperplastic adenomatous polyps/serrated adenomas. A distinct form of colorectal neoplasia. Am. J. Surg. Pathol. 1990; 14; 524-537.
78. Hasegawa S, Mitsuyama K, Kawano H et al. Endoscopic discrimination of sessile serrated adenomas from other serrated lesions. Oncol. Lett. 2010; 2; 785-789.
79. Oka S, Tanaka S, Hiyama T et al. Clinicopathologic and endoscopic features of colorectal serrated adenoma: differences between polypoid and superficial types. Gastrointest. Endosc. 2004; 59; 213-219.
80. Haramis AP, Begthel H, Van den Born M et al. De novo crypt formation and juvenile polyposis on BMP inhibition in mouse intestine. Science 2004; 303; 1684-1686.
81. Kim KM, Lee EJ, Kim YH, Chang DK, Odze RD. KRAS mutations in traditional serrated adenomas from Korea herald an aggressive phenotype. Am. J. Surg. Pathol. 2010; 34; 667-675.
82. O'Brien MJ, Yang S, Mack C et al. Comparison of microsatellite instability, CpG island methylation phenotype, BRAF and KRAS status in serrated polyps and traditional adenomas indicates separate pathways to distinct colorectal carcinoma end points. Am. J. Surg. Pathol. 2006; 30; 1491-1501.
83. Ha SY, Lee SM, Lee EJ et al. Filiform serrated adenoma is an unusual, less aggressive variant of traditional serrated adenoma. Pathology 2012; 44; 18-23.
84. Yantiss RK, Oh KY, Chen YT, Redston M, Odze RD. Filiform serrated adenomas: a clinicopathologic and immunophenotypic study of 18 cases. Am. J. Surg. Pathol. 2007; 31; 1238-1245.
85. Kakar S, Deng G, Cun L, Sahai V, Kim YS. CpG island methylation is frequently present in tubulovillous and villous adenomas and correlates with size, site, and villous component. Hum. Pathol. 2008; 39; 30-36.
86. Eslami-Varzaneh F, Washington K, Robert ME, Kashgarian M, Goldblum JR, Jain D. Benign fibroblastic polyps of the colon: a histologic, immunohistochemical, and ultrastructural study. Am. J. Surg. Pathol. 2004; 28; 374-378.
87. Groisman GM, Polak-Charcon S. Fibroblastic polyp of the colon and colonic perineurioma: 2 names for a single entity? Am. J. Surg. Pathol. 2008; 32; 1088-1094.
88. Groisman GM, Polak-Charcon S, Appelman HD. Fibroblastic polyp of the colon: clinicopathological analysis of 10 cases with emphasis on its common association with serrated crypts. Histopathology 2006; 48; 431-437.
89. Pai RK, Mojtahed A, Rouse RV et al. Histologic and molecular analyses of colonic perineurial-like proliferations in serrated polyps: perineurial-like stromal proliferations are seen in sessile serrated adenomas. Am. J. Surg. Pathol. 2011; 35; 1373-1380.
90. Zamecnik M, Chlumska A. Perineurioma versus fibroblastic polyp of the colon. Am. J. Surg. Pathol. 2006; 30; 1337-1339.
91. Jass JR, Do KA, Simms LA et al. Morphology of sporadic colorectal cancer with DNA replication errors. Gut 1998; 42; 673-679.
92. Jenkins MA, Hayashi S, O'Shea AM et al. Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study. Gastroenterology 2007; 133; 48-56.
93. Alexander J, Watanabe T, Wu TT, Rashid A, Li S, Hamilton SR. Histopathological identification of colon cancer with microsatellite instability. Am. J. Pathol. 2001; 158; 527-535.
94. Jass JR, Iino H, Ruszkiewicz A et al. Neoplastic progression occurs through mutator pathways in hyperplastic polyposis of the colorectum. Gut 2000; 47; 43-49.
95. Snover DC. Sessile serrated adenoma/polyp of the large intestine: a potentially aggressive lesion in need of a new screening strategy. Dis. Colon Rectum 2011; 54; 1205-1206.
96. Ribic CM, Sargent DJ, Moore MJ et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 2003; 349; 247-257.
97. Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J. Clin. Oncol. 2010; 28; 1254-1261.
98. Pai RK, Jayachandran P, Koong AC et al. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features. Am. J. Surg. Pathol. 2012; 36; 744-752.
99. Chirieac LR, Shen L, Catalano PJ, Issa JP, Hamilton SR. Phenotype of microsatellite-stable colorectal carcinomas with CpG island methylation. Am. J. Surg. Pathol. 2005; 29; 429-436.
100. Bond CE, Umapathy A, Ramsnes I et al. p53 mutation is common in microsatellite stable, BRAF mutant colorectal cancers. Int. J. Cancer 2012; 130; 1567-1576.
101. Popovici V, Budinska E, Tejpar S et al. Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer. J. Clin. Oncol. 2012; 30; 1288-1295.
102. Samowitz WS, Sweeney C, Herrick J et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res. 2005; 65; 6063-6069.
103. Barault L, Charon-Barra C, Jooste V et al. Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. Cancer Res. 2008; 68; 8541-8546.
104. Yagi K, Akagi K, Hayashi H et al. Three DNA methylation epigenotypes in human colorectal cancer. Clin. Cancer Res. 2010; 16; 21-33.
105. Ogino S, Kawasaki T, Kirkner GJ, Suemoto Y, Meyerhardt JA, Fuchs CS. Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer. Gut 2007; 56; 1564-1571.
106. Whitehall VL, Wynter CV, Walsh MD et al. Morphological and molecular heterogeneity within nonmicrosatellite instability-high colorectal cancer. Cancer Res. 2002; 62; 6011-6014.
107. Ogino S, Kawasaki T, Kirkner GJ, Loda M, Fuchs CS. CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J. Mol. Diagn. 2006; 8; 582-588.
108. Jass JR, Smith M. Sialic acid and epithelial differentiation in colorectal polyps and cancer-a morphological, mucin and lectin histochemical study. Pathology 1992; 24; 233-242.
109. Tuppurainen K, Makinen JM, Junttila O et al. Morphology and microsatellite instability in sporadic serrated and non-serrated colorectal cancer. J. Pathol. 2005; 207; 285-294.
110. Garcia-Solano J, Perez-Guillermo M, Conesa-Zamora P et al. Clinicopathologic study of 85 colorectal serrated adenocarcinomas: further insights into the full recognition of a new subset of colorectal carcinoma. Hum. Pathol. 2010; 41; 1359-1368.
111. Laiho P, Kokko A, Vanharanta S et al. Serrated carcinomas form a subclass of colorectal cancer with distinct molecular basis. Oncogene 2007; 26; 312-320.
112. Stefanius K, Ylitalo L, Tuomisto A et al. Frequent mutations of KRAS in addition to BRAF in colorectal serrated adenocarcinoma. Histopathology 2011; 58; 679-692.
113. Garcia-Solano J, Conesa-Zamora P, Trujillo-Santos J, Makinen MJ, Perez-Guillermo M. Tumour budding and other prognostic pathological features at invasive margins in serrated colorectal adenocarcinoma: a comparative study with conventional carcinoma. Histopathology 2011; 59; 1046-1056.
114. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 2004; 351; 337-345.
115. Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 2008; 359; 1757-1765.
116. Prahallad A, Sun C, Huang S et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012; 483; 100-103.